Education
About Us
Working with TipRanks
Follow Us
Lixte Biotechnology Holdings (LIXT)
NASDAQ:LIXT
Total Valuation
Lixte Biotechnology Holdings has a market cap or net worth of $25.40M. The enterprise value is ―.
Market Cap$25.40M
Enterprise Value―
Share Statistics
Lixte Biotechnology Holdings has 6,270,540 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding6,270,540
Owned by Insiders2.13%
Owned by Institutions1.39%
Financial Efficiency
Lixte Biotechnology Holdings’s return on equity (ROE) is -4.34 and return on invested capital (ROIC) is -431.93%.
Return on Equity (ROE)-4.34
Return on Assets (ROA)-3.13
Return on Invested Capital (ROIC)-431.93%
Return on Capital Employed (ROCE)-4.32
Revenue Per Employee0.00
Profits Per Employee-1.79M
Employee Count2
Asset Turnover0.00
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Lixte Biotechnology Holdings is ―. Lixte Biotechnology Holdings’s PEG ratio is 0.03.
PE Ratio―
PS Ratio0.00
PB Ratio5.52
Price to Fair Value5.52
Price to FCF-1.44
Price to Operating Cash Flow-4.51
PEG Ratio0.03
Income Statement
In the last 12 months, Lixte Biotechnology Holdings had revenue of 0.00 and earned -3.59M in profits. Earnings per share was -1.59.
Revenue0.00
Gross Profit0.00
Operating Income-3.57M
Pretax Income-3.59M
Net Income-3.59M
EBITDA-3.57M
Earnings Per Share (EPS)-1.59
Cash Flow
In the last 12 months, operating cash flow was -2.58M and capital expenditures 10.00, giving a free cash flow of -2.58M billion.
Operating Cash Flow-2.58M
Free Cash Flow-2.58M
Free Cash Flow per Share-0.41
Dividends & Yields
Lixte Biotechnology Holdings pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.56
52-Week Price Change92.86%
50-Day Moving Average4.36
200-Day Moving Average3.00
Relative Strength Index (RSI)43.76
Average Volume (3m)178.92K
Important Dates
Lixte Biotechnology Holdings upcoming earnings date is ―, ―.
Last Earnings Date―
Next Earnings Date―
Ex-Dividend Date―
Financial Position
Lixte Biotechnology Holdings as a current ratio of 3.26, with Debt / Equity ratio of 0.00%
Current Ratio3.26
Quick Ratio3.26
Debt to Market Cap0.00
Net Debt to EBITDA0.29
Interest Coverage Ratio0.00
Taxes
In the past 12 months, Lixte Biotechnology Holdings has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00
Enterprise Valuation
Lixte Biotechnology Holdings EV to EBITDA ratio is -0.99, with an EV/FCF ratio of -1.11.
EV to Sales0.00
EV to EBITDA-0.99
EV to Free Cash Flow-1.11
EV to Operating Cash Flow-1.11
Balance Sheet
Lixte Biotechnology Holdings has $5.34M in cash and marketable securities with $0.00 in debt, giving a net cash position of $5.34M billion.
Cash & Marketable Securities$5.34M
Total Debt$0.00
Net Cash$5.34M
Net Cash Per Share$0.85
Tangible Book Value Per Share$0.37
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin0.00%
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%
Analyst Forecast
The average price target for Lixte Biotechnology Holdings is ―, which is 11.43% higher than the current price. The consensus rating is ―
Price Target―
Price Target Upside―
Analyst Consensus―
Analyst Count0
Revenue Growth Forecast―
EPS Growth Forecast―